Last reviewed · How we verify
PlasmaLyte as maintenance fluid
PlasmaLyte is a marketed maintenance fluid developed by University Hospital, Antwerp, with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and recognized efficacy as a maintenance fluid. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | PlasmaLyte as maintenance fluid |
|---|---|
| Sponsor | University Hospital, Antwerp |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
- Clinical Effects of Ringers Lactate Versus Sterofundin/ Plasmalyte Solution in Patients With Sepsis (NA)
- Effect of VExUS Ultrasound Protocol (Venous Excess Ultrasound) on Perioperative Fluid Management, on the Incidence of Postoperative Pulmonary Complications and Postoperative Acute Kidney Injury in Patients Undergoing Thoracic Surgery (NA)
- Goal-directed Fluid Therapy During Deep Inferior Epigastric Perforator (DIEP) Free Flap Breast Reconstruction (PHASE4)
- Better Evidence for Selecting Transplant Fluids (PHASE3)
- Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (PHASE3)
- Decision Support for Intraoperative Low Blood Pressure (NA)
- Goal Directed Fluid Administration for Kidney Transplantation (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |